Keytruda could boost economy

A new report, commissioned by MSD, projects the potential that anti PD-1/PD-L1 inhibitors could have beyond improving survival, if used in all eligible Australian cancer patients.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here